2024
Coverage with Influenza, Respiratory Syncytial Virus, and COVID-19 Vaccines Among Nursing Home Residents — National Healthcare Safety Network, United States, November 2024
Reses H, Segovia G, Dubendris H, Barbre K, Ananth S, Lape-Newman B, Wong E, Stillions M, Rowe T, Mothershed E, Wallender E, Twentyman E, Wiegand R, Patel P, Benin A, Bell J. Coverage with Influenza, Respiratory Syncytial Virus, and COVID-19 Vaccines Among Nursing Home Residents — National Healthcare Safety Network, United States, November 2024. MMWR Morbidity And Mortality Weekly Report 2024, 73: 1052-1057. PMID: 39570790, PMCID: PMC11581205, DOI: 10.15585/mmwr.mm7346a2.Peer-Reviewed Original ResearchConceptsRespiratory syncytial virusRespiratory syncytial virus vaccineNational Healthcare Safety NetworkSyncytial virusVaccination coverageSusceptible to severe outcomesHealth and Human Services regionsRespiratory virus seasonCOVID-19 vaccineCDC's National Healthcare Safety NetworkInfluenza vaccineVirus seasonSevere complicationsRespiratory virusesAssociated with respiratory illnessInfluenzaNursing home residentsSafety NetworkRespiratory illnessSevere outcomesReport vaccinationElevated riskSARS-CoV-2VaccineIndex levels
2004
Invasive Pneumococcal Disease among Navajo Adults, 1989–1998
Watt J, O'Brien K, Benin A, Whitney C, Robinson K, Parkinson A, Reid R, Santosham M. Invasive Pneumococcal Disease among Navajo Adults, 1989–1998. Clinical Infectious Diseases 2004, 38: 496-501. PMID: 14765341, DOI: 10.1086/381198.Peer-Reviewed Original ResearchConceptsInvasive pneumococcal diseaseNavajo adultsPneumococcal diseaseEpidemiology of IPDRates of IPDPneumococcal polysaccharide vaccineCase fatality rateGeneral US populationPercent of casesBlack personsPolysaccharide vaccineAnnual incidenceActive surveillanceMedical recordsElevated riskPrevention strategiesUS populationDiseaseCorresponding ratesAdditional researchAdultsUnited StatesRiskPatientsVaccine